All In Biotech

Drug Trial Radar · NCT00624767

A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients

A Phase 2, Randomized, Crossover Study to Evaluate the Effect of Intranasal Insulin and NovoLog on Postprandial Glycemic Control in Type 2 Diabetic Patients

Last checked: Nov 20, 2026Latest source record: May 20, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Mar 2008

Primary completion

Apr 2008

Study completion May 2008

Sponsor

Sponsor type
Industry
First posted
Feb 27, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Insulin is a hormone which is produced by the human pancreas for the lowering of blood sugar. In patients who don't produce enough insulin, additional insulin must be given several times per day by injections. Nastech Pharmaceutical Company Inc. has developed a new insulin nasal spray, as a possible way to improve patient compliance with intensive insulin treatment plans. This study is being conducted to see how Nastech's insulin nasal spray affects post-meal glucose levels compared with rapid acting insulin (i.e., insulin aspart) in Type 2 diabetics who are already taking oral antidiabetic medications and/or insulin therapy. Insulin aspart is marketed as NovoLog® in the United States. The safety of insulin nasal spray and how well it is tolerated as compared to NovoLog will also be evaluated.

Conditions

  • Diabetes Mellitus

Interventions

  • Insulin (recombinant human insulin)Drug

    Insulin Nasal Spray at doses up to 200 IU.

  • NovoLogDrug

    NovoLog at doses up to 30 IU

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect on postprandial glycemic control of intranasal insulin compared to NovoLogTime frame: 4 hour Profile

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Diabetes and Glandular Disease Research Associates

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.